JP5090423B2 - モルホリノプリン誘導体 - Google Patents
モルホリノプリン誘導体 Download PDFInfo
- Publication number
- JP5090423B2 JP5090423B2 JP2009236444A JP2009236444A JP5090423B2 JP 5090423 B2 JP5090423 B2 JP 5090423B2 JP 2009236444 A JP2009236444 A JP 2009236444A JP 2009236444 A JP2009236444 A JP 2009236444A JP 5090423 B2 JP5090423 B2 JP 5090423B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituents selected
- alkylamino
- mmol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YJGPBDTYCWJGEX-UHFFFAOYSA-N CC(C)(C)OC(N(C)c(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl)=O Chemical compound CC(C)(C)OC(N(C)c(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl)=O YJGPBDTYCWJGEX-UHFFFAOYSA-N 0.000 description 1
- VQLYVJDDZMXVAF-UHFFFAOYSA-N CC(C)(C)OC(N(C)c(nc1)ncc1-c1nc(N2CCOCC2)c2nc[n](CC3COCC3)c2n1)=O Chemical compound CC(C)(C)OC(N(C)c(nc1)ncc1-c1nc(N2CCOCC2)c2nc[n](CC3COCC3)c2n1)=O VQLYVJDDZMXVAF-UHFFFAOYSA-N 0.000 description 1
- WSHLFIJGHOVUFO-FQVRHNBASA-N CC(C)(C)OC(N(C)c(nc1)ncc1C1=N[C@H]2N(CC3COCC3)C(C)=NC2C(N2CCOCC2)=N1)=O Chemical compound CC(C)(C)OC(N(C)c(nc1)ncc1C1=N[C@H]2N(CC3COCC3)C(C)=NC2C(N2CCOCC2)=N1)=O WSHLFIJGHOVUFO-FQVRHNBASA-N 0.000 description 1
- XNRIKJPJINSPRL-UHFFFAOYSA-N CNc(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl Chemical compound CNc(nc1)ncc1-c(nc1[n]2CC3COCC3)nc(N3CCOCC3)c1nc2Cl XNRIKJPJINSPRL-UHFFFAOYSA-N 0.000 description 1
- JEVGFJHCXRAHLJ-UHFFFAOYSA-N CS(N(CC1)CCN1c1nc2c(N3CCOCC3)nc(-c(cc3)cnc3N)nc2[n]1CC1COCC1)(=O)=O Chemical compound CS(N(CC1)CCN1c1nc2c(N3CCOCC3)nc(-c(cc3)cnc3N)nc2[n]1CC1COCC1)(=O)=O JEVGFJHCXRAHLJ-UHFFFAOYSA-N 0.000 description 1
- ZZAKLGGGMWORRT-UHFFFAOYSA-N CS(N1CCNCC1)(=O)=O Chemical compound CS(N1CCNCC1)(=O)=O ZZAKLGGGMWORRT-UHFFFAOYSA-N 0.000 description 1
- IZDYYCLYTQYTHQ-AWEZNQCLSA-N C[C@@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O Chemical compound C[C@@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O IZDYYCLYTQYTHQ-AWEZNQCLSA-N 0.000 description 1
- IZDYYCLYTQYTHQ-CQSZACIVSA-N C[C@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O Chemical compound C[C@H](CN(CC1)c2nc3c(N4CCOCC4)nc(-c4cnc(NC)nc4)nc3[n]2CC(F)(F)F)N1C(C)=O IZDYYCLYTQYTHQ-CQSZACIVSA-N 0.000 description 1
- MFJDBCRDNQDMTF-UHFFFAOYSA-N Cc(nc(N)nc1)c1-c(nc1[n]2CC3CC3)nc(N3CCOCC3)c1nc2N(CC1)CCN1S=O Chemical compound Cc(nc(N)nc1)c1-c(nc1[n]2CC3CC3)nc(N3CCOCC3)c1nc2N(CC1)CCN1S=O MFJDBCRDNQDMTF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009236444A JP5090423B2 (ja) | 2008-10-14 | 2009-10-13 | モルホリノプリン誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008264797 | 2008-10-14 | ||
| JP2008264797 | 2008-10-14 | ||
| JP2009121690 | 2009-05-20 | ||
| JP2009121690 | 2009-05-20 | ||
| JP2009236444A JP5090423B2 (ja) | 2008-10-14 | 2009-10-13 | モルホリノプリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011001339A JP2011001339A (ja) | 2011-01-06 |
| JP2011001339A5 JP2011001339A5 (enExample) | 2012-09-20 |
| JP5090423B2 true JP5090423B2 (ja) | 2012-12-05 |
Family
ID=42106564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009236444A Expired - Fee Related JP5090423B2 (ja) | 2008-10-14 | 2009-10-13 | モルホリノプリン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8097622B2 (enExample) |
| EP (1) | EP2336132B1 (enExample) |
| JP (1) | JP5090423B2 (enExample) |
| KR (1) | KR101614976B1 (enExample) |
| CN (1) | CN102245607B (enExample) |
| AU (1) | AU2009304789B2 (enExample) |
| BR (1) | BRPI0920199A2 (enExample) |
| CA (1) | CA2740471C (enExample) |
| CO (1) | CO6362009A2 (enExample) |
| DK (1) | DK2336132T3 (enExample) |
| ES (1) | ES2452541T3 (enExample) |
| IL (1) | IL212278A (enExample) |
| MX (1) | MX2011003490A (enExample) |
| MY (1) | MY156456A (enExample) |
| NZ (1) | NZ592761A (enExample) |
| PL (1) | PL2336132T3 (enExample) |
| PT (1) | PT2336132E (enExample) |
| RU (1) | RU2490269C2 (enExample) |
| TW (1) | TWI378933B (enExample) |
| WO (1) | WO2010044401A1 (enExample) |
| ZA (1) | ZA201102449B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011521968A (ja) * | 2008-05-30 | 2011-07-28 | ジェネンテック， インコーポレイテッド | プリンｐｉ３ｋ阻害剤化合物および使用方法 |
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| BR112012011188A2 (pt) * | 2009-11-12 | 2021-06-29 | F.Hoffmann - La Roche Ag | ''composto,composição farmacêutica e uso de um composto" |
| CN102260263A (zh) * | 2010-05-26 | 2011-11-30 | 四川大学 | 一类二苯胺基嘌呤衍生物及制备方法和医药用途 |
| EP2593455B1 (en) | 2010-07-14 | 2015-03-18 | F.Hoffmann-La Roche Ag | Purine compounds selective for i3 p110 delta, and methods of use |
| SG10201510347QA (en) | 2010-12-16 | 2016-01-28 | Hoffmann La Roche | Tricyclic pi3k inhibitor compounds and methods of use |
| US9334271B2 (en) | 2011-10-28 | 2016-05-10 | Novarits Ag | Purine derivatives and their use in the treatment of disease |
| CN103012284A (zh) * | 2012-12-26 | 2013-04-03 | 无锡捷化医药科技有限公司 | 一种2-氨基-5-溴嘧啶类化合物的制备方法 |
| WO2014185368A1 (ja) * | 2013-05-13 | 2014-11-20 | 第一三共株式会社 | ５－｛８－［（３ｒ）－４－アセチル－３－メチルピペラジン－１－イル］－６－モルホリン－４－イル－９－（２，２，２－トリフルオロエチル）－９ｈ－プリン－２－イル｝ピリミジン－２－アミン、およびその薬理上許容される塩の新規な結晶、およびその製造方法 |
| WO2014185367A1 (ja) * | 2013-05-13 | 2014-11-20 | 第一三共株式会社 | モルホリノプリン誘導体の製造方法 |
| US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
| KR102369925B1 (ko) * | 2013-10-04 | 2022-03-03 | 우니베르시태트 바젤 | 구조적으로 제한된 PI3K 및 mTOR 억제제 |
| MY185268A (en) | 2015-03-30 | 2021-04-30 | Daiichi Sankyo Co Ltd | Pyrazole derivative useful as pi3k inhibitor |
| US10765681B2 (en) | 2016-02-05 | 2020-09-08 | Academia Sinica | Purine compounds possessing anticancer activity |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| US11208442B2 (en) | 2016-12-02 | 2021-12-28 | Daiichi Sankyo Company, Limited | Endo-beta-N-acetylglucosaminidase |
| EP3360865A1 (en) | 2017-02-13 | 2018-08-15 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of cyclopropyldiketopiperazines, and of a key intermediate of ds-5272 |
| TWI837231B (zh) | 2018-11-29 | 2024-04-01 | 日商第一三共股份有限公司 | 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途 |
| CN113368114B (zh) * | 2020-03-10 | 2022-04-22 | 四川大学 | 一种吗啉嘧啶类化合物的抗肿瘤应用 |
| JP2024511996A (ja) * | 2021-03-17 | 2024-03-18 | タンゴ セラピューティクス， インコーポレイテッド | 抗がん剤としてのプリン誘導体 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864145A (en) * | 1959-06-02 | 1961-03-29 | Thomae Gmbh Dr K | Novel purines and a process for their manufacture |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP3810017B2 (ja) | 2000-04-27 | 2006-08-16 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| ATE503743T1 (de) | 2000-04-27 | 2011-04-15 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
| WO2002088112A1 (en) | 2001-04-27 | 2002-11-07 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| AU2003284142A1 (en) | 2002-10-15 | 2004-05-04 | Synta Pharmaceuticals Corp | Aromatic bicyclic heterocyles to modulate 1L-12 production |
| ES2389253T3 (es) | 2002-10-25 | 2012-10-24 | Zenyaku Kogyo Kabushiki Kaisha | Compuestos heterocíclicos y agentes antitumorales que comprenden los mismos como ingrediente activo |
| AU2003294249A1 (en) | 2002-11-08 | 2004-06-03 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| KR101052482B1 (ko) | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용 |
| AU2005249380C1 (en) * | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| AU2006302148B2 (en) | 2005-10-07 | 2012-12-06 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kalpha |
| EA016945B1 (ru) | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| DK2024372T3 (da) | 2006-04-26 | 2010-09-20 | Hoffmann La Roche | Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor |
| KR20090021155A (ko) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제제로서의 피리미딘 유도체 |
| CA2650290C (en) | 2006-04-26 | 2015-11-17 | Genentech, Inc. | Pharmaceutical compounds |
| EP2046799B1 (en) | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| GB0611152D0 (en) | 2006-06-06 | 2006-07-19 | Ucb Sa | Therapeutic agents |
| PL2050749T3 (pl) | 2006-08-08 | 2018-03-30 | Chugai Seiyaku Kabushiki Kaisha | Pochodna pirymidyny jako inhibitor pi3k i jej zastosowanie |
| WO2008023161A1 (en) | 2006-08-23 | 2008-02-28 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| WO2008023180A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
| JP2010503651A (ja) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | 増殖性障害の治療用のＰＩ３Ｋ及びｍＴＯＲ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−フェニルピリミジン誘導体 |
| WO2008032089A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032036A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032028A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032091A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032060A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| CN101563340A (zh) | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物 |
| GB0620818D0 (en) | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| TW200831084A (en) | 2006-11-21 | 2008-08-01 | Genelabs Tech Inc | Anti-viral compounds |
| US7888352B2 (en) | 2006-12-07 | 2011-02-15 | Piramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| ES2571028T3 (es) | 2006-12-07 | 2016-05-23 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso |
| ES2381895T3 (es) | 2007-02-06 | 2012-06-01 | Novartis Ag | Inhibidores de PI 3-quinasa y métodos para su uso |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| US20080233127A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| WO2008125833A1 (en) | 2007-04-12 | 2008-10-23 | Piramed Limited | Pharmaceutical compounds |
| BRPI0810641A2 (pt) | 2007-04-12 | 2019-09-24 | Hoffmann La Roche | "compostos farmacêuticos". |
| GB0707087D0 (en) | 2007-04-12 | 2007-05-23 | Piramed Ltd | Pharmaceutical compounds |
| WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
| WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
| JP5539190B2 (ja) | 2007-06-12 | 2014-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | チアゾロピリミジン類及びホスファチジルイノシトール−３キナーゼのインヒビターとしてのそれらの使用 |
| WO2009007748A2 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| CN101932587A (zh) | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
| EP2209786B1 (en) | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
| US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
| ES2600919T3 (es) | 2007-10-05 | 2017-02-13 | Index Pharmaceuticals Ab | Oligonucleótidos para el tratamiento o alivio de edema |
| KR20100083170A (ko) | 2007-10-16 | 2010-07-21 | 와이어쓰 엘엘씨 | 티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 ｍＴＯＲ 키나제 및 ＰＩ3 키나제 억제제로서의 용도 |
| CA2701292C (en) | 2007-10-25 | 2015-03-24 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| JP5638955B2 (ja) | 2007-10-26 | 2014-12-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体 |
| GB0721095D0 (en) | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| US20090149458A1 (en) | 2007-11-27 | 2009-06-11 | Wyeth | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS |
| GB0723748D0 (en) | 2007-12-04 | 2008-01-16 | Ucb Pharma Sa | Therapeutic agents |
| WO2009071895A1 (en) | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Fused thiazole and thiophene derivatives as kinase inhibitors |
| GB0723747D0 (en) | 2007-12-04 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
| WO2009071890A1 (en) | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Tricyclic kinase inhibitors |
| CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
| CN102014914A (zh) | 2008-01-15 | 2011-04-13 | 惠氏有限责任公司 | 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成 |
| WO2009093981A1 (en) | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Triazine compounds as kinase inhibitors |
| US8557807B2 (en) | 2008-01-24 | 2013-10-15 | Signal Rx Pharmaceuticals, Inc. | Thienopyranones as kinase inhibitors |
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| BRPI0906805A2 (pt) | 2008-01-25 | 2015-07-14 | Astrazeneca Ab | Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação |
| CL2009000241A1 (es) | 2008-02-07 | 2010-09-03 | Chugai Pharmaceutical Co Ltd | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. |
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
-
2009
- 2009-10-12 TW TW098134442A patent/TWI378933B/zh not_active IP Right Cessation
- 2009-10-13 PT PT98205792T patent/PT2336132E/pt unknown
- 2009-10-13 EP EP09820579.2A patent/EP2336132B1/en not_active Not-in-force
- 2009-10-13 CA CA2740471A patent/CA2740471C/en not_active Expired - Fee Related
- 2009-10-13 ES ES09820579.2T patent/ES2452541T3/es active Active
- 2009-10-13 AU AU2009304789A patent/AU2009304789B2/en not_active Ceased
- 2009-10-13 WO PCT/JP2009/067738 patent/WO2010044401A1/ja not_active Ceased
- 2009-10-13 DK DK09820579.2T patent/DK2336132T3/da active
- 2009-10-13 KR KR1020117008413A patent/KR101614976B1/ko not_active Expired - Fee Related
- 2009-10-13 JP JP2009236444A patent/JP5090423B2/ja not_active Expired - Fee Related
- 2009-10-13 MY MYPI2011001420A patent/MY156456A/en unknown
- 2009-10-13 CN CN200980151585.4A patent/CN102245607B/zh not_active Expired - Fee Related
- 2009-10-13 RU RU2011119525/04A patent/RU2490269C2/ru not_active IP Right Cessation
- 2009-10-13 BR BRPI0920199A patent/BRPI0920199A2/pt not_active IP Right Cessation
- 2009-10-13 MX MX2011003490A patent/MX2011003490A/es active IP Right Grant
- 2009-10-13 PL PL09820579T patent/PL2336132T3/pl unknown
- 2009-10-13 NZ NZ592761A patent/NZ592761A/en not_active IP Right Cessation
- 2009-10-14 US US12/579,175 patent/US8097622B2/en not_active Expired - Fee Related
-
2011
- 2011-04-01 ZA ZA2011/02449A patent/ZA201102449B/en unknown
- 2011-04-12 IL IL212278A patent/IL212278A/en not_active IP Right Cessation
- 2011-05-09 CO CO11056552A patent/CO6362009A2/es active IP Right Grant
- 2011-11-30 US US13/308,239 patent/US8309546B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5090423B2 (ja) | モルホリノプリン誘導体 | |
| EP3733663B1 (en) | 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer | |
| EP4549439A1 (en) | Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof | |
| SG185617A1 (en) | Purinone derivative | |
| WO2011041399A2 (en) | Pi3k (delta) selective inhibitors | |
| WO2010005558A2 (en) | Pi3k isoform selective inhibitors | |
| TW202204365A (zh) | 作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合 | |
| EP2571884A2 (en) | Mtor selective kinase inhibitors | |
| JP2022529152A (ja) | Ｃｄ７３阻害剤 | |
| JP2011236198A (ja) | モルホリノプリン誘導体 | |
| EP3546458A1 (en) | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| EP2065388B1 (en) | Pyrazolopyrimidine derivative | |
| JP5565913B2 (ja) | 三環性ピラゾロピリミジン誘導体 | |
| RS59213B1 (sr) | 6-morfolinil-2-pirazolil-9h-purinski derivati i njihova primena kao pi3k inhibitora | |
| JP2025519493A (ja) | Ｄｇｋ阻害剤としての三環式トリアゾロ化合物 | |
| HK1158189B (en) | Morpholinopurine derivative | |
| JP2012067087A (ja) | 三環性ピラゾロピリミジン誘導体 | |
| HK40040029A (en) | 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer | |
| HK40040029B (en) | 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer | |
| HK1164308A (en) | Tricyclic pyrazolopyrimidine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120807 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120807 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20120807 |
|
| TRDD | Decision of grant or rejection written | ||
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20120829 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120903 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120912 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150921 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5090423 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |